Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Ponvory (Janssen)
- INDICATIONS: Treatment of relapsing forms of multiple sclerosis.
- CLASS: Sphingosine1-phosphate receptor modulator
- HALF-LIFE: ~33 hours
- FDA APPROVAL DATE: 03/18/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alemtuzumab, Amiodarone, anti-arrhythmic drugs, QT prolonging drugs, drugs that may decrease heart rate , attenuated vaccines, beta-blockers, Carbamazepine, Carbamazepine, CYP3A4 and UGT1A1 inducers, Digoxin, Diltiazem, Phenytoin, Procainamide, Quinidine, Rifampin, Sotalol, Verapamil - PREGNANCY: May cause fetal harm. Contraception is advised.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
